Cure rates for adult acute lymphoblastic leukaemia (ALL) in developing countries are significantly lower because of problems unique to these countries. Recent studies have reported complete response rates for any induction regimen of more than 90% in adult ALL patients. This study was conducted to evaluate the response rate of induction chemotherapy in adult ALL patients in the
Introduction
Acute lymphoblastic leukaemia (ALL) is a heterogeneous group of disorders that result from the clonal proliferation and expansion of malignant lymphoid blast cells in the bone marrow, blood and other organs. It vary with respect to the morphologic, cytogenetic, molecular, and immunologic features of the neoplastic cells 1-3 .
Contemporary ALL treatment programmes include induction, intensified consolidation, maintenance phases and central nervous system (CNS) prophylaxis that accompanies induction and consolidation 1-10 . The goal of remission induction therapy is haematologic complete remission (CR), as defined by the eradication of morphologically detectable leukaemic cells in blood and bone marrow that is eradication of more than 99 percent of the initial burden of leukaemic cells and the return of normal haematopoiesis and a normal performance status 3,4,9 .
Advances in ALL therapy have led to long-term survival rates of >80% in children. However, only approximately 30-40% of adults achieve long-term disease-free survival 3 . Standard induction of remission of adult ALL includes at least a glucocorticoid, vincristine, an anthracycline and Lasparaginase while intrathecal methotrexate is used for CNS prophylaxis 13 . This modification has been considered in context of our compromised supportive care, and patient's compliance and affordability. Another aim of this study is to correlate the outcome with the initial clinical-haematological characteristics of the patients.
Materials and Methods
In this observational study, thirty five newly diagnosed adult ALL patients between 15 to 60 years of age classified either as L1/L2 (FAB classification) were assigned. The study was carried out in the Department of Haematology, BSMMU from January 2007 to December 2008. Out of 35 patients 5 were dropped; 2 because of early death, and 3 due to resistant disease and remaining 30 were ultimate study sample. Relevant clinical data including laboratory findings were recorded with written consent. Peripheral blood film (PBF) examination (Leishman stain), estimation of Hb (cyanmethaemoglobin method), complete blood count from PBF, bone marrow examination (Leishman stain), cytochemistry (PAS & MPO) by commercially available kit (Sigma kit) were done for diagnosis of the disease and CSF study was done to detect CNS involvement. Cytogenetic study and cell markers were not performed due to lack of facility. For pre-induction evaluation, liver function tests, kidney function tests, serum electrolytes, lactate dehydrogenase (LDH), uric acid, random blood sugar were done by autoanalyzer (Dade Behring, model RXL Max); coagulation assay was done by fully automated coagulometer (Sysmex, model CA-500) & by latex agglutination method. Routine examination of stool & urine, ECG, X-ray chest were also done. All study population received induction therapy with modified MRC UKALL XII/ECOG E2993 protocol (Table I) . Patients with CNS involvement were treated by intrathecal triple chemotherapy (methotrexate 12.5mg, cytarabine 30mg, corticosteroids 40mg) weekly for 16 times. G-CSF was used for early peripheral recovery of neutrophils. Full blood count was done at 3-day interval until the recovery of peripheral blood count. Bone marrow examination was done after phase 1 at day 28+ and after phase 2 therapy with the peripheral recovery to assess remission status. Morphologic CR was assumed by <5% blast cells in the bone marrow with no peripheral circulating blasts, platelets >100 x10 9 /L, an absolute neutrophil count >1.5x10 9 /L and Hb level >10gm/dl. Patients who did not achieve CR after phase 2 therapy considered as non responders (NR) or resistant cases. Precautions were taken to minimize the risk of infection. Patients with fever were treated with broad-spectrum antibiotics and anti fungal agents. Platelet or fresh frozen plasma transfusion were given to patients with the evidence of bleeding. A haemoglobin level >8 gm/dl was generally maintained by transfusion of red cells concentrate.
Statistical analysis was done using SPSS 17.0. The characteristics of the patients and their response to treatment were compared by chi-square test for univariate analysis. P value less than 0.05 was considered as significant.
Result
Sex, age, WBC count, Hb level, platelet count, percentage of peripheral blood and bone marrow blasts, FAB classification & clinical characteristics at presentation of 30 patients are summarized in Table II . The mean age of the patients was 28.07 years (Range: 15-60 years; SD: ±12.31). Out of 30 cases 22 were male (73%) and 8 were female (27%) giving a male to female ratio of 3:1. Anaemia (Hb level ≤10 gm/dl) was present in 63% of patients, WBC count ≥30X10 9 /L in 43% of patients, thrombocytopenia (platelet count ≤100 x10 9 /L) in 73% of patients and 63% patients had ≥ 90 % blasts in the bone marrow. Statistical analysis was performed taking into account of clinical-pathological characteristics of 30 cases. Out of 30 patients, 12 patients achieved CR after phase 1 therapy (Fig.1) . Presenting WBC count and lymphadenopathy (Table III) were found to have significant influence (P<0.05) on the achievement of CR. Out of 30 patients, 24 patients achieved CR after phase 2 therapy (Fig. 2) . By univariate analysis (Table IV) , statistical significance on achievement of CR was found for sex (male/female; P=0.013), age (<30 years; P=0.028), WBC count (<30x10 9 /L; P=.027), Hb level (>10 mg/dl; P=0.037) and percentage of blast in the bone marrow (<90%; P= 0.037). 
Discussion
Acute lymphoblastic Leukaemia, the most common childhood acute leukaemia, represents about 80% of acute leukaemias; however, it makes up only 20% of adult leukaemias. ALL has an overall incidence of 1 to 1.5 per 100,000 persons and a bimodal distribution. The median age of patients with ALL in most registry studies is between 25 and 35 years 2 .
The clinical-pathological characteristics of 30 adult ALL patients are more or less similar to studies in different countries 14 including Bangladesh 15 except sex distribution, male patients (22/30 or 73%) were greater than female patients (8/30 or 27%) which is more or less similar to a study in Bangladesh 15 . But this is in contrast with the observation of Luciana Annino et al.
14 who found male 59% versus female 41%. The higher incidence of ALL among males in our study may be due to female patients being neglected more and get less opportunity to attend a tertiary medical centre.
In this study among 30 patients, 12(40%) patients after phase 1 and overall 24(80%) patients after phase 2 of induction therapy achieved morphologic CR. The remaining 06(20%) patients though responded initially, ultimately fell in the group of non responders (NR) as the blast percentage was ≥5% at the time of bone marrow evaluation. This result is slightly lower than the original study by Jacob et al. 5 Remission induction of adult ALL patients with intensive chemotherapy using different protocols have shown more or less similar result worldwide. The aim of the induction therapy is always to achieve a better CR rates while minimizing therapy related toxicities, thus reducing morbidity and mortality. The standard induction therapy used in this study resulted in a response rates slightly below the anticipated response rates of developed countries which may be due to prolongation of duration of therapy, poor supports especially during the period of pancytopenia, lack of molecular prognostic markers identification and advanced treatment options or due to little modification of the original protocol. Considering all these settings the response rates of induction therapy used in this study is satisfactory. So this study may have significance for the development of local capacity based effective treatment protocol for ALL in our country. However further large scale randomized study with a long term follow-up should be undertaken to ascertain the success of induction therapy in adult ALL.
